



**Dr. Uzma Zafar, MD**

**Jacinta Cruz, PMHNP-BC**

**5366 S Fort Apache Rd Ste 102, Las Vegas, Nevada 89148**

**axis.psychiatry.lv@gmail.com**

**Ph: (702) 915 – 7001**

**Fax: (702) 909 – 9254**

June 9, 2021

Pharmacy and Therapeutics Committee  
State of Nevada Department of Health and Human Services  
Division of Health Care Financing and Policy  
1100 E William Street, Suite 101  
Carson City, Nevada 89701

RE: Agenda item 6d – Discussion and possible adoption of Psychotropic Agents – Antipsychotics – Atypical Antipsychotics-Oral

To Whom It May Concern:

It is my understanding that there is a review of Oral Atypical Antipsychotics, Agenda item 6d on June 24, 2021, with the Silver State Scripts Board Meeting. I ask that Caplyta be on the State Medicaid at a Preferred Status.

I have found it to have a MOA that is unique and has really distinguished itself from others in weight changes similar to placebo. As you well know compliance continues to be one of the biggest obstacles we face in psychiatry and getting our patient to establish treatment goals to continue to be very difficult and challenging especially due to undesired side effects.

I have had positive experience with Caplyta. Thank you in advance for your consideration of this request.

Best Regards,

Uzma Zafar, MD

Board Certified Psychiatrist